These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31289316)

  • 1. Reversine exhibits antineoplastic activity in JAK2
    Lima K; Carlos JAEG; Alves-Paiva RM; Vicari HP; Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA
    Sci Rep; 2019 Jul; 9(1):9895. PubMed ID: 31289316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia.
    Carlos JAEG; Lima K; Coelho-Silva JL; de Melo Alves-Paiva R; Moreno NC; Vicari HP; de Souza Santos FP; Hamerschlak N; Costa-Lotufo LV; Traina F; Machado-Neto JA
    Cell Oncol (Dordr); 2020 Dec; 43(6):1191-1201. PubMed ID: 32857324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversine triggers mitotic catastrophe and apoptosis in K562 cells.
    Rodrigues Alves AP; Machado-Neto JA; Scheucher PS; Paiva HH; Simões BP; Rego EM; Traina F
    Leuk Res; 2016 Sep; 48():26-31. PubMed ID: 27447890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin exerts multitarget antileukemia activity in JAK2
    Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
    Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
    Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
    Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R
    Parducci NS; Garnique ADMB; Lima K; Carlos JAEG; Fonseca NP; de Miranda LBL; de Almeida BO; Rego EM; Traina F; Machado-Neto JA
    Blood Cells Mol Dis; 2024 Jan; 104():102799. PubMed ID: 37839173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
    Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
    Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
    de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
    Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
    Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
    J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glioma cells by antineoplastic activity of reversine.
    Hirakata C; Lima K; De Almeida BO; De Miranda LBL; Florêncio KGD; Furtado LC; Costa-Lotufo LV; Machado-Neto JA
    Oncol Lett; 2021 Aug; 22(2):610. PubMed ID: 34188712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
    Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
    Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.
    Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Oncotarget; 2015 Oct; 6(30):29573-84. PubMed ID: 26356819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferential killing of p53-deficient cancer cells by reversine.
    Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
    Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
    Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
    J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring redox vulnerabilities in JAK2
    Lima K; Lopes LR; Machado-Neto JA
    Hematol Transfus Cell Ther; 2021; 43(4):430-436. PubMed ID: 32962959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression.
    Woo JK; Kang JH; Shin D; Park SH; Kang K; Nho CW; Seong JK; Lee SJ; Oh SH
    Mol Cancer Ther; 2015 Jul; 14(7):1693-704. PubMed ID: 25882311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.